EXELIXIS, INC. — Investor Relations & Filings

Exelixis, Inc. is an oncology-focused biotechnology company that discovers, develops, and commercializes therapies for cancer treatment. The company's primary commercial product is cabozantinib, a small molecule inhibitor marketed for multiple cancer indications, including neuroendocrine tumors and certain types of carcinoma. Leveraging a genomics-based approach, Exelixis advances a diverse pipeline of potential medicines. Its research and development programs encompass in-house small molecule discovery and an expanding portfolio of biotherapeutics, such as antibody-drug conjugates and bispecific antibodies. The company pursues both next-generation approaches to established targets and first-in-class opportunities to address unmet needs in oncology.